[ad_1]
The “State of the Biopharmaceutical Industry 2022” report has been added to ResearchAndMarkets.com’s offering.
In this “State of the Biopharmaceutical Industry 2022” report, the analyst examines the business environment and trends that are going to shape the biopharmaceutical industry in 2022. The report highlights the most impactful emerging technologies, industry, regulatory, and microeconomic factors that are going to impact and dominate the industry throughout 2022.
As industries emerge from the impact of COVID-19, 2022 will be a year of readjustments and transition for many businesses worldwide. While the ongoing COVID-19 pandemic continues to restrain economic recovery, pharmaceutical companies will continue to leverage innovative technology to enable and accelerate business growth, enhance resilience, and remain competitive in this heavily disrupted business landscape.
Scope
-
The research source in this report is based on the opinions and expectations of 177 global healthcare industry professionals surveyed from November 17, 2021, to December 17, 2021, to gauge the 2022 outlook of the pharmaceutical industry. Respondents rated the anticipated impact of emerging industry , regulatory, macroeconomic and technology trends on the pharmaceutical industry during upcoming 12 months.
-
Components of the report include:
-
Emerging Industry Trends – a snapshot of current attitudes of business leaders towards the emerging industry trends and how they are shaping the future of healthcare industry
-
Emerging Regulatory and Macroeconomic Trends…
Full story available on Benzinga.com
[ad_2]
Source link
